UCLA Health researchers have identified what they describe as the first drug capable of fully reproducing the effects of physical stroke rehabilitation. The study, published in Nature Communications, tested candidate drugs derived from research into how rehabilitation affects the brain at the molecular level. One compound, DDL-920, produced significant recovery in movement control in laboratory mouse models of stroke.

Stroke remains the leading cause of adult disability, with most patients never fully recovering. Currently, no drugs exist for stroke recovery—patients rely solely on physical rehabilitation, which offers only modest results. Dr. S. Thomas Carmichael, the study's lead author and chair of UCLA Neurology, stated the goal is to develop a medicine that produces rehabilitation's effects, moving stroke treatment into an era of molecular medicine.

The research team discovered that strokes damage connections in parvalbumin neurons, which generate gamma oscillations—brain rhythms that coordinate neural networks for movement. Physical rehabilitation restores these gamma oscillations and repairs lost connections. DDL-920, developed in the UCLA lab of Varghese John, specifically excites parvalbumin neurons to produce gamma oscillations, mimicking rehabilitation's effects. Further studies on safety and efficacy are needed before human trials can begin.